Comparison of antiresorptive effect of hormone therapy and ibandronate in postmenopausal osteoporotic women by assessing type I collagen C-telopeptide levels
Restricted accessResearch articleFirst published online June, 2015
Comparison of antiresorptive effect of hormone therapy and ibandronate in postmenopausal osteoporotic women by assessing type I collagen C-telopeptide levels
The aim of this study is to compare the antiresorptive effect of hormone therapy and oral ibandronate in postmenopausal osteoporotic women by measuring bone mineral density (BMD) and degradation products of C-terminal telopeptide of type I collagen (CTX) using serum crosslaps ELISA.
Study design
The study is a randomized comparative trial.
Methods
About 60 women with age > 40 years, having either surgical or medical menopause with T- or Z-score below -2.5 SD were included in the study. They were randomized into two groups of 30 each; one group received conventional hormone therapy (group I) and the other group received ibandronate monthly (group II). The treatment was given for 6 months.
Results
The BMD increased from 0.894 g/cm2 to 0.933 g/cm2 (p < 0.01) in group I and from 0.865 g/cm2 to 0.934 g/cm2 (p < 0.01) in group II. The increase in BMD in group I (4.3%) was less than group II (7.9%) which was significant (p < 0.01). The serum CTX levels also showed significant reduction in both groups after 6 months of therapy; more reduction was seen in group II as compared to group I (41.5% vs. 4.6%, p < 0.01).
Conclusion
Ibandronate can be used as a substitute to hormone therapy in women presenting with osteoporosis. Long-term studies are needed to authenticate the observation.
World Health Organization. Research on the menopause: The 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser1996; 866: 12.
3.
BhattacharyyaSSeigelEAchenbachS. Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. J Bone Miner Res2008; 23(7): 1106–1117.
4.
BiverEBrentanoTChopinF. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: A systematic review. Semin Arthritis Rheum2011; 41: 157–169.
5.
BockOFelsenbergD. Bisphosphonates in the management of postmenopausal osteoporosis–optimizing efficacy in clinical practice. Clin Interv Aging2008; 3(2): 279–297.
6.
EpsteinSDelmasPEmkeyR. Oral ibandronate in the management of postmenopausal osteoporosis: Review of upper gastrointestinal safety. Maturitas2006; 54: 1–10.
7.
CotteFFardellonePMercierF. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int2010; 21: 145–155.
8.
ReginsterJYAdamiSLakatosP. Efficacy and tolerability of once monthly oral ibandronate in postmenopausal osteoporosis: 2 year result from the MOBILE study. Ann Rheum Dis2006; 64: 654–661.
9.
AggarwalNRaveendranAKhandelwalN. Prevalence and related risk factors of osteoporosis in peri- and postmenopausal Indian women. J Midlife Health2011; 2(2): 81–85.
10.
SirisEMillerPBarrett-ConnorE. Design of NORA, the National Osteoporosis Risk Assessment Program: A longitudinal US registry of postmenopausal women. Osteoporos Int1998; 8(Suppl 1): S62–69.
11.
MansonJEChlebowskiRTStefanickML. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA2013; 310(13): 1353–1368.
12.
RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA2002; 288(3): 321–333.
13.
BrunnerRLAragakiABarnabeiV. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause2010; 17(5): 946–954.
14.
RavnPClemmesenBRiisBJ. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone1996; 19(5): 527–533.
15.
BockOFelsenbergD. Bisphosphonates in the management of postmenopausal osteoporosis–optimizing efficacy in clinical practice. Clin Interv Aging2008; 3(2): 279–297.
16.
EastellRRobinsSPColwellT. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int1993; 3(5): 255–260.
17.
BergmannPBodyJJBoonenS. Evidence based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone club. Int J Clin Pract2009; 63(1): 19–26.
18.
SusanLResnickNMParkerRA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA2003; 289(19): 2525–2533.
19.
KawDVashisthaK. Factors influencing the age at menopause. J Obstet Gynecol India1994; 44: 273–277.
20.
RosenquistCFledeliusCChristgauS. Serum crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone related degradation products from C terminal telopeptides of type I collagen. Clin Chem1998; 44(11): 2281–2290.
21.
ChubbSA. Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin Biochem2012; 45: 928–935.
22.
EpsteinSDelmasPEmkeyR. Oral ibandronate in the management of postmenopausal osteoporosis: Review of upper gastrointestinal safety. Maturitas2006; 54: 1–10.
23.
CotteFFardellonePMercierF. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int2010; 21: 145–155.
24.
ReginsterJYAdamiSLakatosP. Efficacy and tolerability of once monthly oral ibandronate in postmenopausal osteoporosis: 2 year result from the MOBILE study. Ann Rheum Dis2006; 64: 654–661.
25.
ChristgauSBitsch-JensenOBjarnaHanover. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone2000; 26(5): 505–511.
26.
BharadwajJAKendurkarSMVaidyaPR. Age and symptomatology of menopause in Indian women. J Postgrad Med1983; 29(3): 218–222.
27.
KriplaniABanerjeeK. An overview of age of onset of menopause in northern India. Maturitas2005; 52(3): 199–204.
28.
KakkarVKaurDChopraK. Assessment of the variation in menopausal symptoms with age, education and working/non-working status in north-Indian sub population using menopause rating scale (MRS). Maturitas2007; 57(3): 306–314.
29.
HassaHTanirHMTekinB. Possible factors affecting the age at menopause among women in the central anatolian region of Turkey. Clin Exp Obstet Gynecol2006; 33(1): 59–60.
30.
BielaU. Determinants of the age at natural menopause. Przegl Lek2002; 59(3): 165–169.
31.
SirpaETiitenenAValimakiM. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab2004; 89(2): 626–631.
